OWCP (OWC Pharmaceutical Research) Other Long-Term Liabilities: $5.22 Mil (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OWC Pharmaceutical Research Other Long-Term Liabilities?

OWC Pharmaceutical Research OWCP -90.00% Other Long-Term Liabilities is $5.22 Mil as of Sep. 2019.

OWC Pharmaceutical Research's other long-term liabilities for the quarter that ended in Sep. 2019 was $5.22 Mil.

OWC Pharmaceutical Research's quarterly other long-term liabilities declined from Mar. 2019 ($12.65 Mil) to Jun. 2019 ($4.84 Mil) but then increased from Jun. 2019 ($4.84 Mil) to Sep. 2019 ($5.22 Mil).

OWC Pharmaceutical Research's annual other long-term liabilities stayed the same from Dec. 2016 ($0.00 Mil) to Dec. 2017 ($0.00 Mil) but then increased from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($12.56 Mil).

OWC Pharmaceutical Research Other Long-Term Liabilities Related Terms

OWC Pharmaceutical Research Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research Other Long-Term Liabilities Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 12.56

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.70 12.56 12.65 4.84 5.22

OWC Pharmaceutical Research Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $5.22 Mil mean?
OWC Pharmaceutical Research (OWCP) has a Other Long-Term Liabilities of $5.22 Mil as of Sep. 2019. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OWC Pharmaceutical Research and its competitors.
Is OWC Pharmaceutical Research's Other Long-Term Liabilities too high?
OWC Pharmaceutical Research's current Other Long-Term Liabilities is $5.22 Mil.
How does OWC Pharmaceutical Research's Other Long-Term Liabilities compare to PARNF and CANB?
OWC Pharmaceutical Research's Other Long-Term Liabilities of $5.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OWC Pharmaceutical Research and its competitors. OWC Pharmaceutical Research's current Other Long-Term Liabilities is $5.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current Other Long-Term Liabilities of $5.22 Mil. The current Other Long-Term Liabilities is $5.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current Other Long-Term Liabilities is $5.22 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.